Choose VONJO for a strong treatment effect on spleen volume reduction1

29% of VONJO patients with platelet counts <50 x 109/L 
achieved ≥35% spleen volume reduction (SVR)1

VONJO can offer a 10x increase in patients achieving SVR

Percentage of Patients Achieving ≥35% SVR 
From Baseline to Week 24

graph

See PERSIST-2 study design

83 percent

of patients with platelet counts <50 x 109/L 
on VONJO experienced any SVR compared 
to 56% of patients on BAT.1*

Median Percent Change From Baseline in Spleen Volume at Week 24†‡

Graph
Graph

 

  • *Only those patients with an available SVR percent change value at Week 24 were included in the waterfall plot.
  • †Dropout rates in VONJO and BAT arms were 26% and 44%, respectively.
  • ‡The median SVR from baseline to Week 24 for patients with platelet counts <50 x 109/L was 27.3% in the VONJO arm vs 0.9% in the BAT arm.

Beyond low platelet counts, consider the impact of myelofibrosis (MF) symptoms in your patients with thrombocytopenia

Modified MFSAF v2.0 captured how the patient was feeling based on 6 symptoms of MF2:

Icon

 EARLY SATIETY

Icon

ABDOMINAL DISCOMFORT

Icon

 NIGHT SWEATS

Icon

 ITCHING

icon

 PAIN UNDER LEFT RIBS

Icon

 BONE PAIN

Limitations: 

  • The TSS endpoint was not met; therefore, no conclusions regarding the benefits or risks of VONJO can be established based on the following post-hoc analysis from PERSIST-2 
  • These data are not included in the VONJO Prescribing Information

Total symptom score (TSS) results for patients 
with platelet counts <50 x 109/L2

Percentage of Patients Achieving ≥50% Reduction in TSS (Modified MFSAF v2.0) From Baseline to Week 24

Graph

Click below to see additional efficacy data from the PERSIST-2 trial.

Limitations: 

  • This is a post-hoc analysis of an exploratory endpoint from the PERSIST-2 trial and is not appropriately powered
  • No conclusions regarding the benefits or risks of VONJO can be established based on the following data
  • These data are not included in the VONJO Prescribing Information

Myelofibrosis is a hematologic malignancy requiring patients to undergo routine blood cell count monitoring and/or receive RBC/platelet transfusions; therefore, the PERSIST-2 trial included changes in hematologic parameters as exploratory endpoints.3

Platelet Count Levels Through Week 242§

Graph
Graph
  • §Platelet-TI at baseline and received no platelet transfusions on study.2
  • ||BAT included ruxolitinib (45%).3

Limitations:

  • These are post-hoc analyses of exploratory endpoints from the PERSIST-2 trial and are not appropriately powered
  • No conclusions regarding the benefits or risks of VONJO can be established based on the following data
  • These data are not included in the VONJO Prescribing Information

Percentage of Patients Achieving Transfusion Independence Over Any 12-Week Interval Through Week 242¶

Graph
Graph

Percentage of Patients With ≥50% Transfusion Reduction Over Any 12-Week Interval Through Week 242¶

Graph
Graph
  • ||BAT included ruxolitinib (45%).3
  • Among those requiring RBC transfusions at baseline, as per Gale criteria. 
  • BAT=best available therapy; CI=confidence interval; IQR=interquartile range; MFSAF=Myelofibrosis Symptom Assessment Form; MOA=mechanism of action; NCCN=National Comprehensive Cancer Network® (NCCN®); RBC=red blood cell; TI=transfusion independent.
  • References: 1. VONJO. Prescribing information. CTI BioPharma Corp.; 2023. 2. Data on File. Sobi, Inc. 2023. 3. Mascarenhas J, et al. JAMA Oncol. 2018;4(5):652-659.